


How effective is the Pfizer-BioNTech vaccine in protecting adolescents against symptomatic infection and severe COVID-19?




We looked at cases of **symptomatic SARS-CoV-2 infection** and **severe COVID-19** in Brazilian and Scottish adolescents

after receiving **two-doses of Pfizer-BioNTech vaccine**

We analysed:



503,776 COVID-19 tests




127,168 COVID-19 tests



In both countries, **vaccine effectiveness against symptomatic infection:**

- 1. Was higher during the Delta period than the Omicron period*.**
- 2. Began to decrease 27 days after the second-dose vaccine**




**14-27 days post second-dose vaccine.*

Read our full plain English summary of this paper at: <https://edin.ac/3zFrTUR>

During the Omicron period, by 98 days post-second dose...

vaccine effectiveness against symptomatic infection fell to:



vaccine effectiveness against severe COVID-19 remained high in Brazil* at

82.7%

**unable to replicate results in Scotland due to a lack of data*

Conclusion

Two doses are unlikely to prevent the long-term spread of the SARS-CoV-2 virus, but they do provide longer-term protection against severe COVID-19.

These national analyses suggest the need for additional protection against symptomatic infection through further vaccine doses